Purdue Pharma L.P.

Track this case

Case overview

Case Number:

7:19-bk-23649

Court:

New York Southern

Nature of Suit:

Firms

Companies

Government Agencies

Sectors & Industries:

  1. November 20, 2024

    Lawyers In Purdue Bankruptcy Get OK For Millions In Fees

    More than 150 lawyers, investment bankers and financial advisers representing the creditors committee of bankrupt OxyContin maker Purdue Pharma LP billed $21.2 million as the high-stakes case reignited this summer, according to a Law360 tally of interim fee applications.

  2. November 14, 2024

    Maryland Seeks To Undo Litigation Pause In Purdue Appeal

    The state of Maryland argued in New York federal court Thursday that it should be allowed to pursue claims against the Sackler family members who own bankrupt OxyContin maker Purdue Pharma LP, and that a temporary injunction currently blocking a flood of litigation should be thrown out.

  3. November 13, 2024

    Purdue, Sacklers Agree To Terms As New Ch. 11 Deal Nears

    Purdue Pharma LP has agreed to some terms for a new settlement with certain members of the Sackler family, including key provisions governing the scope of liability releases and how much money the family will contribute to pay victims of the opioid crisis who are claimants in the OxyContin maker's bankruptcy case, according to an update provided by co-mediators.

  4. November 04, 2024

    Purdue Buys Time For Creditor Deal, Eletson Plan Confirmed

    Facing a litigation stay deadline after the U.S. Supreme Court overturned its Chapter 11 plan, OxyContin maker Purdue Pharma was given a new one-month extension of the stay so that its creditors and the Sacklers can continue mediating to settle claims.

  5. October 31, 2024

    Purdue Gets More Time For Deal, 'Substantial' Progress Made

    Bankrupt OxyContin maker Purdue Pharma LP on Thursday won more time to continue mediating a new settlement with its owners — certain members of the Sackler family — and reported that it is nearing a deal, in a bid to avoid having one of the most complex Chapter 11 cases in U.S. history tumble into a litigation free-for-all.

  6. October 29, 2024

    Purdue Creditors Can Sue Sacklers For $11.5B

    Creditors of bankrupt OxyContin maker Purdue Pharma LP will get the right to sue the company's owners — certain members of the Sackler family — and others for $11.5 billion, should they choose to do so, a New York judge said on Tuesday.

  7. October 28, 2024

    5 Things About The Quest For Sacklers' Billions Overseas

    Many uncertainties hang over the long-running saga of bankrupt opioid maker Purdue Pharma LP. One of the biggest, for creditors, is how to handle the Sackler family that owns the company — or more specifically — their billions of dollars held overseas.

  8. October 23, 2024

    Purdue Seeks Another Extension Of Mediation On New Plan

    OxyContin maker Purdue Pharma is asking a New York bankruptcy judge for another month to try to work out a replacement for its Chapter 11 plan and opioid settlement that were shot down by the U.S. Supreme Court in June.

  9. October 21, 2024

    Purdue Opioid Victims Group Backs Creditors In Litigation Bid

    A group of more than 60,000 victims is backing creditors of Purdue Pharma LP in their efforts to potentially sue members of the Sackler family who own the bankrupt opioid maker, and has also warned against protracted legal battles if current mediation efforts fail.

  10. October 15, 2024

    Sacklers Say Opioid Claims Can't Undo Purdue Transfers

    The family that owns bankrupt drugmaker Purdue Pharma LP is challenging an effort by creditors to claw back billions of dollars transferred by the company to Sackler trusts, telling a New York federal judge that opioid claims fail and can't be used to prove that Purdue made the distributions knowing it was insolvent.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!